BRIEF—Polyplus buys Belgian CDMO Xpress Biologics

Cell and gene therapy solutions provider Polyplus has acquired Xpress Biologics, a contract manufacturing and development organization (CDMO), with the goal of expanding its offering.

The acquisition of Xpress, a specialist in the production of plasmid DNA and protein using microbial expression systems, will augment Polyplus’ plasmid DNA engineering tech and its portfolio of services.

Polyplus chief executive Mario Philips said: “We will combine our deep understanding of the gene-therapy viral vector manufacturing process with research and High-Quality grade plasmid production immediately and expect to have the capability to supply GMP grade plasmids around Q1 of 2023.”

Xpress Biologics’ CDMO services will continue to be offered, including for Research, GLP, High Quality and GMP grade proteins and plasmids DNA for multiple uses.

Financial particulars were not disclosed.